検索結果

Data And Statistics | About Senju | SENJU Pharmaceutical

Sales Revenue 2021.3 2022.3* 2023.3* 2024.3* 2025.3* Sales Revenue 40.7 40.8 46.4 48.9 48.9 Operating Profit 5.4 6.9 7.4 7.1 2.4 Ordinary Profit 8.0 9.1 8.7 9.1 2.9 Total Assets 75.8 83.9 88.2 98.4 10

CEO Message | About Senju | SENJU Pharmaceutical

Since Senju was established in 1947, we have been making efforts for more than 70 years to develop excellent medicines and services focusing on the ophthalmology field through our unique ideas and R&a

Compliance System | Our Initiatives for Society/Environment | About Senju | SENJU Pharmaceutical

Code of Conduct for Compliance The directors, employees and other members of Senju Pharmaceutical Co., Ltd. (“SENJU”) will act in compliance not only with the law but will operate under a high standar

お知らせ | 千寿製薬株式会社

April 6, 2026 Launch of “Avarept® Ophthalmic Suspension 0.3%” in Japan, A Novel Treatment of Dry Eye Disease through TRPV1 Inhibition（PDF） December 22, 2025 Obtained manufacturing and marketing approv

お知らせ | 千寿製薬株式会社